![VX-661 Catalog No.:M10067-10 17-dien-8-yl]-2-oxoethyl 2-methylpropanoate](https://cdn.shopify.com/s/files/1/0389/1897/9723/files/1686100964283_1.png?v=1686100987)
Pay in 4 interest-free payments of $28.98 Learn more
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
17-dien-8-yl]-2-oxoethyl 2-methylpropanoate
PubMed PMID: 12389628
InChi: InChI=1S/C22H25N3O4/c26-18-4-1-5-19(28-11-13-6-7-13)20(18)17-9-15(14-3-2-8-23-10-14)16-12-29-22(27)25-21(16)24-17/h1
4H2O/c1-20(2
9 nM for PKCβI and PKCβII
VX-661 Catalog No.:M10067-10 17-dien-8-yl]-2-oxoethyl 2-methylpropanoateTezacaftor, also known asVX 661, is CFTR modulator. VX 661 is potentially useful for treatment of cystic fibrosis disease. Cystic fibrosis (CF) is a genetic disease caused by defects in the CF transmembrane regulator (CFTR) gene, which encodes an epithelial chloride channel. The most common mutation, 508CFTR, produces a protein that is misfolded and does not reach the cell membrane. VX 661 can correct trafficking of 508CFTR and partially restore